Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings.

Published

Journal Article

One hundred ten of 175 patients with aplastic anemia conditioned by cyclophosphamide had sustained engraftment of marrow from human leukocyte antigen (HLA)-identical siblings and lived for more than 6 months. Forty-nine of the 110 patients developed chronic graft-versus-host disease between 85 and 464 days. Ninety-seven patients are alive from 1.4 to 11 years after engraftment; 13 died between 208 and 726 days. Twenty of the 36 surviving patients with chronic graft-versus-host disease have Karnofsky performance scores of 100%, 7 of 90%, 5 of 80%, 1 of 70%, 2 of 60%, and 1 of 40%. Our analysis, using a binary logistic regression model, identified three factors predicting chronic graft-versus-host disease: moderate to severe acute graft-versus-host disease with an estimated relative risk of 11.65; increasing patient age; and the use of viable donor buffy coat cells in addition to the marrow to prevent graft rejection. The last two factors were significant only in patients without acute graft-versus-host disease.

Full Text

Duke Authors

Cited Authors

  • Storb, R; Prentice, RL; Sullivan, KM; Shulman, HM; Deeg, HJ; Doney, KC; Buckner, CD; Clift, RA; Witherspoon, RP; Appelbaum, FA; Sanders, JE; Stewart, PS; Thomas, ED

Published Date

  • April 1, 1983

Published In

Volume / Issue

  • 98 / 4

Start / End Page

  • 461 - 466

PubMed ID

  • 6340576

Pubmed Central ID

  • 6340576

Electronic International Standard Serial Number (EISSN)

  • 1539-3704

International Standard Serial Number (ISSN)

  • 0003-4819

Digital Object Identifier (DOI)

  • 10.7326/0003-4819-98-4-461

Language

  • eng